Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
25
×
national blog main
national top stories
25
×
life sciences
boston blog main
boston top stories
new york blog main
new york top stories
san francisco blog main
national
san diego blog main
san diego top stories
san francisco top stories
clinical trials
raleigh-durham blog main
raleigh-durham top stories
startups
texas blog main
texas top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
indiana blog main
indiana top stories
seattle blog main
seattle top stories
wisconsin blog main
wisconsin top stories
deals
novartis
cancer
amgen
investing
biogen
boston
eli lilly
ipo
vc
What
new
25
×
drug
medicines
bio
biotech
drugs
fda
ipo
million
roundup
therapeutics
companies
life
medicine
raised
approval
cancer
class
genetic
medical
migraine
precision
research
science
wave
year
adds
aims
approved
big
brings
ceo
cholesterol
company
deal
develop
developing
disease
diseases
earlier
Language
unset
Current search:
biotech
×
" national top stories "
×
new
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
3 years ago
Two Days, Six IPOs, and $1B Raised for Biotech Research & More
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com
4 years ago
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
@xconomy.com
4 years ago
Podcast: How San Diego is Building a Biotech Ecosystem – Genomics & Precision Medicine Experts Weigh in
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Allergan Wins FDA Nod for First Migraine Pill in New Class of Medicines
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
JLabs’ Luby Takes the Reins at TMC Innovation Institute in Houston
@xconomy.com
5 years ago
Brii Bio’s Alliance with VBI Vaccines Adds Hepatitis B Drug to Pipeline
@xconomy.com
5 years ago
Ireland to Sequence 400K Genomes With New Precision Medicine Effort
@xconomy.com
5 years ago
TP Therapeutics Names New CEO, Gets $80M More For Cancer Drug Push
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com
5 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines
@xconomy.com
6 years ago
Will New Study Cut Guesswork for Depression Medicine Prescriptions?
@xconomy.com
6 years ago
Synthorx Raises $63M to Advance Suite of Enhanced Cytokine Drugs